Non-functioning adrenal incidentalomas are associated with elevated D-dimer levels

Journal of Endocrinological Investigation

Volumn 32, Issue 4, 2009, Pages 338-343

  Yener, S ^a   Comlekci, A ^a   Akinci, B ^a   Secil, M ^a   Demir, T ^a   Ertilav, S ^a   Yesil, S ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Adrenal adenoma; D dimer

Indexed keywords

CORTICOTROPIN; D DIMER; FIBRINOGEN; HYDROCORTISONE; PRASTERONE SULFATE; URIC ACID; VON WILLEBRAND FACTOR;

ADRENAL DISEASE; ADRENAL GLAND; ADRENAL INCIDENTALOMA; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; CONTROLLED STUDY; DEXAMETHASONE SUPPRESSION TEST; DISEASE ASSOCIATION; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; METABOLIC SYNDROME X;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENOCORTICOTROPIC HORMONE; ANTIFIBRINOLYTIC AGENTS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; HYDROCORTISONE; INCIDENTAL FINDINGS; INSULIN RESISTANCE; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 70349503666     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345724     Document Type: Article

References (31)

1. Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002, 87: 998-1003.
2. Erbil Y, Ademoglu E, Ozbey N, et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006, 30: 1665-1671 (Pubitemid 44411221)
3. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 2001, 54: 797-804. (Pubitemid 34208891)
4. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000, 85: 1440-1448 (Pubitemid 32289484)
5. Ermetici F, Malavazos AE, Corbetta S, et al. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 2007, 56: 686-692 (Pubitemid 46574732)
6. Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab 2001, 86: 5301-5306 (Pubitemid 33070251)
7. Ambrosi B, Sartorio A, Pizzocaro A, et al. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes 2000, 108: 294-298 (Pubitemid 30458601)
8. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006, 4: 1186-1193 (Pubitemid 43756691)
9. Khuseyinova N, Koenig W. Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care 2006, 12: 412-419 (Pubitemid 44341705)
10. Baldassarre D, Amato M, Pustina L, et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis 2007, 191: 403-408 (Pubitemid 46400703)
11. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen.]. Acta Haematol 1957, 17: 237-246
12. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007, 157: 545-559
13. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000, 85: 637-644
14. Sartorio A, Conti A, S Ferrera S, et al. Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing's syndrome and in patients with adrenal incidentaloma. Eur J Endocrinol 1998, 138: 146-152 (Pubitemid 28131090)
15. Midorikawa S, Sanada H, Hashimoto S, et al. Analysis of cortisol secretion in hormonally inactive adrenocortical incidentalomas: study of in vitro steroid secretion and immunohistochemical localization of steroidogenic enzymes. Endocr J 2001, 48: 167-174 (Pubitemid 32499749)
16. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982, 54: 131-138
17. Stubbs M, York DA. Central glucocorticoid regulation of parasympathetic drive to pancreatic B-cells in the obese fa/fa rat. Int J Obes 1991, 15: 547-553
18. Mangos GJ, Walker BR, Kelly JJ, et al. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000, 13: 1155-1160
19. Sudhir K, Jennings GL, Esler MD, et al. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension 1989, 13: 416-421 (Pubitemid 19132181)
20. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 2005, 112: 332-340 (Pubitemid 41022073)
21. Albiger N, Testa RM, Almoto B, et al. Patients with Cushing's syndrome have increased intimai media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006, 38: 405-410 (Pubitemid 44047963)
22. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84: 2664-2672 (Pubitemid 30641990)
23. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002, 87: 4872-4878 (Pubitemid 35316318)
24. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004, 140: 589-602.
25. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994, 90: 2236-2240 (Pubitemid 24354307)
26. Lowe GD, Rumley A, Sweetnam PM, Yarnell JW, Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 2001, 86: 822-827 (Pubitemid 32834192)
27. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001, 103: 2323-2327 (Pubitemid 32448793)
28. Lowe GD, Rumley A, McMahon AD, et al. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004, 24: 1529-1534 (Pubitemid 39050452)
29. Pradhan AD, LaCroix AZ, Langer RD, et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004, 110: 292-300.
30. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older nondiabetic men. Atherosclerosis 2005, 181: 101-108 (Pubitemid 40804699)
31. Nieuwdorp M, Stroes ES, Meijers JC, Büller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005, 5: 155-159